CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Assembly Biosciences, Inc. - ASMB CFD

16.7689
0.66%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.2622
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02504 %
Charges from full value of position ($-4.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02504%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002818 %
Charges from full value of position ($0.54)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002818%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 16.6589
Open 16.4589
1-Year Change 1775.87%
Day's Range 16.4589 - 17.2589
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 1, 2024 16.7689 0.3100 1.88% 16.4589 17.4389 16.4589
Oct 31, 2024 16.6589 -0.3000 -1.77% 16.9589 17.2689 16.0989
Oct 30, 2024 16.8389 0.3800 2.31% 16.4589 17.7389 16.4589
Oct 29, 2024 17.4489 1.9900 12.87% 15.4589 17.8989 15.4589
Oct 28, 2024 16.5889 -0.1200 -0.72% 16.7089 17.4689 16.4589
Oct 25, 2024 16.7089 0.4900 3.02% 16.2189 17.0589 16.2189
Oct 24, 2024 16.6189 0.5500 3.42% 16.0689 16.9589 16.0289
Oct 23, 2024 16.0789 -0.2500 -1.53% 16.3289 16.4889 15.6589
Oct 22, 2024 16.2789 0.0700 0.43% 16.2089 16.5489 15.6189
Oct 21, 2024 16.4189 -1.5900 -8.83% 18.0089 18.1189 16.2089
Oct 18, 2024 18.1989 0.7000 4.00% 17.4989 18.7489 17.4989
Oct 17, 2024 17.8689 0.6300 3.65% 17.2389 18.2189 16.9589
Oct 16, 2024 17.4889 -0.7800 -4.27% 18.2689 18.2689 17.0589
Oct 15, 2024 18.2589 1.0100 5.86% 17.2489 18.4589 17.2389
Oct 14, 2024 16.9689 -0.4600 -2.64% 17.4289 18.5589 16.7889
Oct 11, 2024 17.0289 1.0400 6.50% 15.9889 17.2689 15.9889
Oct 10, 2024 15.4689 -0.6100 -3.79% 16.0789 16.0789 15.3589
Oct 9, 2024 15.8589 1.3900 9.61% 14.4689 16.6389 14.4689
Oct 8, 2024 14.3689 0.3600 2.57% 14.0089 14.7089 14.0089
Oct 7, 2024 14.2689 -0.2800 -1.92% 14.5489 14.6589 14.2589

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Assembly Biosciences, Inc. Company profile

About Assembly Biosciences Inc

Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).

Equity composition

Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.

Industry: Proprietary & Advanced Pharmaceuticals

Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

US elections: Trump leads the polls, but tariff talk spooks investors

As the US elections get closer we look at how Trump’s tariff plans could affect markets.

15:02, 22 October 2024

Gold markets to trade

Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.

08:00, 21 October 2024

US earnings seasons off to a solid start as focus shifts to tech giants

The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.

14:31, 17 October 2024

ECB Preview: cooling growth and inflation call for another rate cut

Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.

12:41, 16 October 2024

Australian labour force data forecast to reveal stable jobs market

Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.

07:41, 15 October 2024

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

People also watch

US100

20,083.20 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0250%
Short position overnight fee 0.0028%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

68,802.35 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

70.95 Price
+2.700% 1D Chg, %
Long position overnight fee 0.0104%
Short position overnight fee -0.0324%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+1.880% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading